BostonSight Publishes Study Highlighting Prose Lens Utilization for Drug Delivery

BostonSight announced it has published a study: “Utilizing PROSE as a Drug Delivery Device for Preservative-Free Cyclosporine 0.05% for the Treatment of Dry Eye Disease: A Pilot Study” in the journal Clinical Ophthalmology. The open-label, prospective, non-comparative clinical trial highlights the investigative approach, concepts, and scientific questions regarding the use of PROSE or scleral lenses as a drug delivery device.

According to BostonSight, PROSE treatment uses customized scleral lenses to treat patients with corneal irregularities and ocular surface diseases. A scleral lens rests on the sclera and vaults over the cornea, creating a new surface over the damaged cornea. The space between the cornea and the lens is filled with preservative-free saline, creating a fluid reservoir that bathes the cornea continuously to promote comfort, healing, and relief.  

BostonSight conducted testing using cyclosporine 0.05%, known commercially as Restasis, in the scleral lens reservoir for the treatment of dry eye disease. 

“Ultimately, we anticipate that our research in this area will lead to additional ocular management strategies to improve ocular health and the lives of our patients,” said Daniel Brocks, MD, Chief Medical Officer at BostonSight and the study’s research lead.

Read the study here: https://www.dovepress.com/articles.php?article_id=97126.